Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1134-1139 , September 2009

Pharmacokinetics of Mycophenolic Acid Administered 3 Times Daily after Hematopoietic Stem Cell Transplantation with Reduced-Intensity Regimen

  • Bernard Royer

      Affiliations

    • Inserm, U645, Besançon, France; Université de Franche-Comté, Besançon, France; EFS, BFC, Besançon, France
    • CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Besançon, France
    • ,
  • Fabrice Larosa

      Affiliations

    • CHU Besançon, Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France
    • ,
  • Faezeh Legrand

      Affiliations

    • CHU Besançon, Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France
    • ,
  • Pauline Gerritsen-van Schieveen

      Affiliations

    • CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Besançon, France
    • ,
  • Michel Bérard

      Affiliations

    • CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Besançon, France
    • ,
  • Jean-Pierre Kantelip

      Affiliations

    • CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Besançon, France
    • ,
  • Eric Deconinck

      Affiliations

    • Inserm, U645, Besançon, France; Université de Franche-Comté, Besançon, France; EFS, BFC, Besançon, France
    • CHU Besançon, Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France
    • Corresponding Author InformationCorrespondence to: Eric Deconinck, MD, PhD, CHU Besançon, Service d'Hématologie, Hôpital Jean Minjoz, bvd Fleming, 25030 Besançon, France.

Received 25 February 2009 ,Accepted 18 April 2009.

References 

  1. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation. 2006;82:1004–1012
  2. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145–154
  3. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005;11:495–505
  4. Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant. 2005;35:1089–1093
  5. Giaccone L, McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005;106:4381–4388
  6. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol. 2007;20:281–294
  7. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14:246–255
  8. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030
  9. Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant. 2006;12:454–465
  10. Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999;67:499–504
  11. van Hest RM, Doorduijn JK, de Winter BC, et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit. 2007;29:353–360
  12. Jacobson P, El-Massah SF, Rogosheske J, et al. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant. (in press).
  13. Perez-Simon JA, Martino R, Caballero D, et al. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2008;14:664–671
  14. The ESH-EBMT Handbook 5th edition, Haematopoietic Stem Cell Transplantation. European Group for Blood and Marrow Transplantation (EBMT). Handbook on Haematopoietic Stem Cell Transplantation. J. Apperley, E. Carreras, E. Gluckman, A. Gratwohl, T. Masszi Eds, ESH-EBMT, forum service editore, Genoa, Italy.
  15. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  16. Na-Bangchang K, Supasyndh O, Supaporn T, Banmairuroi V, Karbwang J. Simple and sensitive high-performance liquid chromatographic. J Chromatogr B Biomed Sci Appl. 2000;738:169–173
  17. Larosa F, Marmier C, Robinet E, et al. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2005;35:859–868
  18. Jenke A, Renner U, Richte M, et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001;15:176–184
  19. Okamura A, Yamamori M, Shimoyama M, et al. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2008;88:104–110
  20. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5:2937–2944
  21. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003
  22. Jacobson P, Rogosheske J, Barker JN, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005;78:486–500
  23. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2004;10:246–258
  24. Haentzschel I, Freiberg-Richter J, Platzbecker U, et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2008;42:113–120
  25. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27:354–361
  26. Saint-Marcoux F, Debord J, Hoizey G, et al. Statistics of MMF dose adjustment on ISBA, a free website for dose adjustment of immunosuppressive drugs [abstract]. Ther Drug Monit. 2007;29:241
  27. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet. 2005;44:1317–1328
  28. Saint-Marcoux F, Royer B, Debord J, et al. Pharmacokinetic modelling and development of Bayesian estimators for the therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic cell transplantation. Clin Pharmacokinet (in press).

 Financial disclosure: See Acknowledgments on page 1138.

PII: S1083-8791(09)00213-4

doi: 10.1016/j.bbmt.2009.04.011

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1134-1139 , September 2009

Article Tools

* Image Usage & Resolution